RxDoctor Payments Data

Shariar Borbor, MD

Family Medicine · Azusa, CANPI 1477868933

Payments from drug & device makers

$1,393in general payments, 2019–2025

Across 70 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$206
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$186
  • Cranial Technologies, Inc$140
  • Amgen$128
  • Sanofi Pasteur Inc.$121
  • Merck$92
  • plus $520 from 13 others

What the payments were for

  • Food & beverage$1,393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,393 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$8,249
Medicare patients
38
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$96,645
JanuviaSitagliptin Phosphate63$66,668
OtezlaApremilast13$62,705
JardianceEmpagliflozin53$50,527
RybelsusSemaglutide22$24,710
EliquisApixaban19$20,070
MyrbetriqMirabegron14$19,340
FarxigaDapagliflozin Propanediol12$14,991
Atorvastatin Calcium287$2,246
Wixela InhubFluticasone Propion/Salmeterol22$2,126
Levothyroxine Sodium122$1,993
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,823
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,525
Losartan Potassium154$1,300
LantusInsulin Glargine,hum.Rec.Anlog15$1,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$206$121,355118 claims
MerckJanuvia$92$66,66863 claims
AmgenOtezla$128$62,70513 claims
Boehringer IngelheimJardiance$28$50,52753 claims
Astellas Pharma US IncMyrbetriq$30$19,34014 claims
AstraZenecaFarxiga$39$14,99112 claims
Sanofi-aventis U.S. LLCLantus$33$1,02715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Azusa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →